Clinical Trial Update: Letrozole Plus Oral Cyclophosphamide Plus/Minus Sorafenib as Primary Systemic Treatment in Breast Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating letrozole plus oral cyclophosphamide with or without sorafenib as primary systemic therapy for breast cancer; current status is unknown…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Letrozole (letrozole)
• Sorafenib (Sorafenib)

Snippet

Sponsor: University of Turin, Italy | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN